MP60-18 DAROLUTAMIDE REAL-WORLD DOUBLET AND TRIPLET UTILIZATION IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (mHSPC): US COMMUNITY UROLOGY SETTING

You have accessJournal of UrologyProstate Cancer: Advanced (Including Drug Therapy) III (MP60)1 May 2024MP60-18 DAROLUTAMIDE REAL-WORLD DOUBLET AND TRIPLET UTILIZATION IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (mHSPC): US COMMUNITY UROLOGY SETTING Benjamin Lowentritt, Lauren Curry, Rakesh Singh, Nicholas Lazarou, Lorraine O'Donnell, James Eller, Katie Grant, Israel Arango-Hisijara, Bashir Kalayeh, Jeff Kirkwold, Audrey Himes, Jay Jhaveri, and Joelle Hamilton Benjamin LowentrittBenjamin Lowentritt , Lauren CurryLauren Curry , Rakesh SinghRakesh Singh , Nicholas LazarouNicholas Lazarou , Lorraine O'DonnellLorraine O'Donnell , James EllerJames Eller , Katie GrantKatie Grant , Israel Arango-HisijaraIsrael Arango-Hisijara , Bashir KalayehBashir Kalayeh , Jeff KirkwoldJeff Kirkwold , Audrey HimesAudrey Himes , Jay JhaveriJay Jhaveri , and Joelle HamiltonJoelle Hamilton View All Author Informationhttps://doi.org/10.1097/01.JU.0001008804.84010.ec.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Darolutamide (DARO) in combination with docetaxel and androgen deprivation therapy (ADT) (triplet therapy TT) is FDA approved and an NCCN Guidelines Category 1 preferred treatment for mHSPC. However, there is limited data on real-world utilization and treatment patterns of DARO plus ADT (doublet therapy DT) for mHSPC. The primary objective of this analysis was to describe the clinical profile of those receiving DT. METHODS: This retrospective descriptive analysis used the largest urology integrated database in the US, PPS Analytics (Specialty Networks) Patient Population Health Management Platform composed of 90 community urology practices. Data acquisition included structured data in electronic medical records and chart abstraction for data in clinical notes. The study included 319 de novo and recurrent mHSPC patients treated with DARO DT or TT between 01/01/2019 and 03/31/2023. Duration of therapy (DOT) may be understated since a patient's end date could have been defined as the end of the study period, 03/31/2023. RESULTS: Of 319 eligible mHSPC patients, 192 (60%) received DT and 127 (40%) received TT. Among the DT cohort, the median age was 75.0 years, 18% of patients were African American, and 66% were White-Non-Hispanic, with the majority of patients (77%) having Medicare coverage. Nearly half of DT patients (42%) had a high Gleason score (≥8) and the mean PSA at start of therapy was 42.3 ng/mL. The majority of patients (83%) initiated ADT followed by DARO and the median time from prostate cancer diagnosis to start of therapy was 73 weeks. At the time of analysis, the median follow-up was 44 weeks and the median DOT was 42 weeks; however, additional follow-up may be needed to further evaluate DOT. Detailed descriptive characteristics for both DT and TT cohorts are available in Table 1. CONCLUSIONS: Results from this community-representative urology database reveal that DARO DT and TT have been adopted routinely in clinical practice. Furthermore, most patients also possessed unfavorable disease characteristics including high Gleason grade grouping and PSA values. These data warrant additional study of treatment patterns in mHSPC as patient characteristics continue to evolve. Source of Funding: This study was supported by Bayer US. Lauren Curry, Rakesh Singh, Israel Arango-Hisijara, Bashir Kalayeh, Jeff Kirkwold, and Jay Jhaveri are employees of Bayer US. Nicholas Lazarou, Lorraine O'Donnell, James Eller, Katie Grant, and Audrey Himes are employees of PPS Analytics © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1007 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Benjamin Lowentritt More articles by this author Lauren Curry More articles by this author Rakesh Singh More articles by this author Nicholas Lazarou More articles by this author Lorraine O'Donnell More articles by this author James Eller More articles by this author Katie Grant More articles by this author Israel Arango-Hisijara More articles by this author Bashir Kalayeh More articles by this author Jeff Kirkwold More articles by this author Audrey Himes More articles by this author Jay Jhaveri More articles by this author Joelle Hamilton More articles by this author Expand All Advertisement PDF downloadLoading ...